BR112019006435A2 - composição apresentando pelo menos um sal farmaceuticamente aceitável do elafibranor solúvel e composição destinada ao tratamento de doenças hepáticas - Google Patents
composição apresentando pelo menos um sal farmaceuticamente aceitável do elafibranor solúvel e composição destinada ao tratamento de doenças hepáticasInfo
- Publication number
- BR112019006435A2 BR112019006435A2 BR112019006435A BR112019006435A BR112019006435A2 BR 112019006435 A2 BR112019006435 A2 BR 112019006435A2 BR 112019006435 A BR112019006435 A BR 112019006435A BR 112019006435 A BR112019006435 A BR 112019006435A BR 112019006435 A2 BR112019006435 A2 BR 112019006435A2
- Authority
- BR
- Brazil
- Prior art keywords
- elafibranor
- composition
- pharmaceutically acceptable
- acceptable salt
- soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção refere-se a uma composição que compreende como princípio ativo um sal farmaceuticamente aceitável do elafibranor caracterizada pelo fato de o sal farmaceuticamente aceitável do elafibranor ser selecionado entre pelo menos um sal de colina, ou de etanol amina, ou de dietanolamina, ou de l-lisina, ou de piperazina, ou de cálcio ou de trometamina. a invenção se refere mais particularmente ao uso dos sais do elafibranor para melhorar a estabilidade e a solubilidade em relação ao elafibranor sob a sua forma de base. esses sais permitem estabelecer formulações farmacêuticas sob diversas formas vantajosas como as injeções intravenosas ou formulações por via enteral que apresentam maior rapidez de absorção, menor variabilidade e, por conseguinte, melhor biodisponibilidade.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1659438A FR3056909B1 (fr) | 2016-09-30 | 2016-09-30 | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
| PCT/EP2017/074701 WO2018060372A1 (fr) | 2016-09-30 | 2017-09-28 | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019006435A2 true BR112019006435A2 (pt) | 2019-06-25 |
Family
ID=58347454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019006435A BR112019006435A2 (pt) | 2016-09-30 | 2017-09-28 | composição apresentando pelo menos um sal farmaceuticamente aceitável do elafibranor solúvel e composição destinada ao tratamento de doenças hepáticas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11185520B2 (pt) |
| EP (1) | EP3518916B1 (pt) |
| CN (1) | CN110234320B (pt) |
| BR (1) | BR112019006435A2 (pt) |
| CA (1) | CA3038726A1 (pt) |
| FR (1) | FR3056909B1 (pt) |
| MX (1) | MX2019003698A (pt) |
| WO (1) | WO2018060372A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220133666A1 (en) | 2016-03-31 | 2022-05-05 | Genfit | Methods of treatment of cholestatic diseases |
| US20200283381A1 (en) * | 2017-11-16 | 2020-09-10 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| EP3830070A1 (en) * | 2018-08-03 | 2021-06-09 | Genfit | Elafibranor salts |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115605192A (zh) * | 2020-05-18 | 2023-01-13 | 基恩菲特公司（Fr） | 用于治疗原发性硬化性胆管炎的伊拉非布拉诺尔 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) * | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| CN101780049A (zh) * | 2009-01-20 | 2010-07-21 | 北京利乐生制药科技有限公司 | 一种以菲诺贝特酸及其盐为主要成份的肠溶固体制剂及其制备方法 |
| CN101863780A (zh) * | 2009-04-15 | 2010-10-20 | 北京利乐生制药科技有限公司 | 一种降血脂药物胆碱盐及其制备方法、医药用途 |
| MX2012006062A (es) * | 2009-11-26 | 2012-06-28 | Genfit | Uso de derivados de 1,3-difenilprop-2-en-1-ona para el tratamiento de trastornos hepaticos. |
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| AU2012212269B2 (en) * | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2016154258A1 (en) * | 2015-03-26 | 2016-09-29 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
-
2016
- 2016-09-30 FR FR1659438A patent/FR3056909B1/fr active Active
-
2017
- 2017-09-28 CA CA3038726A patent/CA3038726A1/fr not_active Abandoned
- 2017-09-28 WO PCT/EP2017/074701 patent/WO2018060372A1/fr unknown
- 2017-09-28 EP EP17777046.8A patent/EP3518916B1/fr active Active
- 2017-09-28 MX MX2019003698A patent/MX2019003698A/es unknown
- 2017-09-28 BR BR112019006435A patent/BR112019006435A2/pt not_active Application Discontinuation
- 2017-09-28 US US16/338,219 patent/US11185520B2/en active Active
- 2017-09-28 CN CN201780073672.7A patent/CN110234320B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| FR3056909B1 (fr) | 2019-04-19 |
| US11185520B2 (en) | 2021-11-30 |
| EP3518916B1 (fr) | 2021-07-07 |
| MX2019003698A (es) | 2020-08-13 |
| CA3038726A1 (fr) | 2018-04-05 |
| US20190274982A1 (en) | 2019-09-12 |
| CN110234320A (zh) | 2019-09-13 |
| FR3056909A1 (fr) | 2018-04-06 |
| EP3518916A1 (fr) | 2019-08-07 |
| CN110234320B (zh) | 2023-10-24 |
| WO2018060372A1 (fr) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006435A2 (pt) | composição apresentando pelo menos um sal farmaceuticamente aceitável do elafibranor solúvel e composição destinada ao tratamento de doenças hepáticas | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| DOP2019000104A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015029455A2 (pt) | compostos químicos | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
| CO2020016582A2 (es) | Sales de sepiapterina farmacéuticamente aceptables | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| BR112016017985A2 (pt) | Composição farmacêutica para administração tópica e usos da mesma na fabricação de medicamentos | |
| AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
| CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
| BR112015013414A2 (pt) | derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| BR112016015175A2 (pt) | Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |